Cognision, a leader in high-performance neurophysiological biomarker solutions, has announced a strategic partnership with SOMNOmedics AG to advance sleep biomarkers in pharmaceutical clinical trials. The collaboration will provide sponsors with next-generation polysomnography (PSG) solutions purpose-built for the rigorous demands of drug development studies.
Addressing Growing Demand for Sleep Endpoints
The partnership addresses the increasing importance of sleep measurements in central nervous system (CNS) drug development. "Sleep endpoints are becoming increasingly important in CNS drug development, from neurodegeneration and neuropsychiatric disorders to pain and emerging psychedelic therapies," said Dr. Igor Korolev, VP of Neuroscience and Digital Health for Cognision.
The collaboration leverages Cognision's expertise in providing complex neurophysiological assessments in regulated research environments with SOMNOmedics' proven compact, mobile, and full-featured PSG technology. Together, the companies will provide an end-to-end solution for sponsors needing precise and reliable sleep architecture data in therapeutic trials.
Technology Integration and Capabilities
SOMNOmedics PSG systems are recognized worldwide for their signal quality, scalable configurations, and adaptability to both inpatient and home use, giving sponsors options for decentralized clinical trials (DCT). The systems will empower sponsors to integrate robust sleep biomarkers into trials of drugs that treat abnormal sleep conditions or that may interfere with healthy sleep with the same confidence expected from Cognision's gold-standard electroencephalography (EEG) and event-related potential (ERP) biomarkers.
All PSG data will be managed within Cognision's regulatory-compliant cloud-based Clinical Trial Data Management System (CTMS), providing near real-time sponsor access for faster decision making and adaptive trial designs. "This partnership delivers best-in-class PSG solutions, streamlined deployment, centralized data management, and highly reproducible automated analysis – without the complexity, risk, and delays often seen in CNS biomarker trials," Dr. Korolev explained.
Setting New Industry Standards
The partnership aims to establish new benchmarks for sleep measurement in pharmaceutical research. "This is not just about providing equipment – it's about ensuring every site, patient, and data point meets the industry's highest standards," said Denise Frahley, Director of US Sales. "Together our operational and technical innovations set a new benchmark for sleep measurement in pharmaceutical research."
The collaboration reinforces Cognision's position as a partner for neurophysiological endpoints in drug development with proven expertise in protocol design, site enablement, data quality oversight, and full analytic capabilities, while expanding SOMNOmedics' reach in the pharmaceutical trial arena. Together, the companies are enabling the next wave of biomarker-driven, precision-targeted CNS drug development.
